id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-022168-qautse9a	Liu, Li	Clinical Use of DNA Vaccines	2017-07-25		.txt	text/plain	7120	321	38	Specifically, the strategies that allow DNA vaccines to overcome antigenic diversity for viral infection and break immune tolerance for cancer therapy are explored. To overcome these obstacles, several approaches focusing on augmenting DNA uptake, maximizing protein expression, and enhancing antigen immunogenicity have been developed and tested in clinical trials. Therefore, one key element to improve DNA vaccine efficacy is to formulate a vaccine with an immunogenic cancer antigen so that it can prime T cells for immune responses. To date, the most successful and encouraging outcomes of using DNA vaccine in the clinical setting were obtained from treatment of malignant diseases where the etiological agent is of foreign viral origin, such as the human papillomavirus (HPV), as these viral agents can readily induce a strong immune response against cancerous cells harboring viral antigens.	./cache/cord-022168-qautse9a.txt	./txt/cord-022168-qautse9a.txt